
MESOBLAST LTD
MESOBLAST LTD (MESO)
WebsitePrice
Market cap
Next catalystQ4 CY2027 interim analysis, when the first 102 patients reach Day 28RYONCIL + ruxolitinib — adult Grade III/IV SR-aGvHD · Phase 3 dataSEC filing ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
PreINDP1P2P3FilingApproved
Other pipelines
Partner / License out
Approved / commercial
Approved
PreINDP1P2P3FilingApproved
History / paused
Financial position
Upcoming milestones
Financial history
Annual trends
| Reported item | ||||
|---|---|---|---|---|
Reported shares and borrowings
Ownership and institutions
| Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|